AbCellera Biologics (ABCL) Assets Average (2021 - 2025)
Historic Assets Average for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2025 value amounting to $1.4 billion.
- AbCellera Biologics' Assets Average fell 168.45% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 168.45%. This contributed to the annual value of $1.4 billion for FY2024, which is 595.42% down from last year.
- According to the latest figures from Q3 2025, AbCellera Biologics' Assets Average is $1.4 billion, which was down 168.45% from $1.4 billion recorded in Q2 2025.
- AbCellera Biologics' Assets Average's 5-year high stood at $1.6 billion during Q2 2022, with a 5-year trough of $1.1 billion in Q1 2021.
- Over the past 5 years, AbCellera Biologics' median Assets Average value was $1.4 billion (recorded in 2024), while the average stood at $1.4 billion.
- Its Assets Average has fluctuated over the past 5 years, first surged by 3971.68% in 2022, then plummeted by 835.02% in 2025.
- Over the past 5 years, AbCellera Biologics' Assets Average (Quarter) stood at $1.2 billion in 2021, then increased by 24.16% to $1.5 billion in 2022, then decreased by 3.01% to $1.5 billion in 2023, then decreased by 8.23% to $1.4 billion in 2024, then rose by 0.17% to $1.4 billion in 2025.
- Its Assets Average was $1.4 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.4 billion in Q1 2025.